ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
31 announcements with these filters
Sanofi India received a GST show cause notice alleging excess input tax credit claims. The total demand, including interest, is Rs. 23.74 Crore.
Sanofi Healthcare India acquired 3,500,000 equity shares (15.20%) of Sanofi India Limited via an inter-se promoter group transfer. The transaction was executed as a block deal.
Hoechst GmbH transferred 3,500,000 shares of Sanofi India Limited to Sanofi Healthcare India Private Limited. This inter-se promoter group transfer represents a 15.20% stake.
Sanofi India disclosed that the State Tax Officer, Tiruvallur dropped a ₹1.07 Crore GST demand for FY 2022-23. The company confirmed no material financial or operational impact.
Sanofi Healthcare India Private Limited, a promoter group entity, proposed an inter-se transfer of up to 3,500,000 shares from Hoechst GmbH. This transaction qualifies for open offer exemption.
The Supreme Court dismissed Sanofi India's petition to quash criminal proceedings. No penalty or operational restriction is imposed on the company at this stage.
Sanofi India Limited received a GST show cause notice regarding product classification for FY 2020-21. The total disputed demand, including tax and penalty, is ₹72.77 Crore.
Sanofi India received a GST refund of ₹1.32 Crore. The Deputy Commissioner also dropped an outstanding demand of ₹75.63 Lakh.
Sanofi India received a favorable income tax order vacating a demand of Rs. 0.73 Crore. The order drops proceedings related to non-deduction of TDS for AY 2019-20.
Sanofi India reported Q2 2026 domestic growth of 8%, driven by a 14% surge in its diabetes business. PBT (before exceptional items) grew 19% YoY to INR 112 crores.
Sanofi India Q2 2026 domestic sales grew 8% YoY, led by a 14% surge in Insulins. Profit Before Tax (PBT) rose 19% YoY to ₹1,123 Mio.
Sanofi India reported Q2'26 domestic sales growth of 8% YoY, driven by a 14% surge in its diabetes business. Management is focusing on business model transformation and operational efficiency.
Sanofi India Ltd reported revenue from operations of ₹437.7 Cr (+7.7% YoY) and net profit of ₹83.5 Cr (+20.1% YoY) for Q1 FY27.
Sanofi India’s board approved Q2 2026 unaudited financial results and reconstituted board committees. It also announced the resignation of a key managerial person.
Sanofi India Limited announced the cessation of Mr. Nakul Verma as Public Affairs & Market Access-Head. He transitions to another role within the Sanofi group effective July 31, 2026.
Mr. Rachid Ayari will resign as Whole Time Director and CFO of Sanofi India on September 30, 2026. He is transitioning to another role within Sanofi group.
Sanofi India Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing details holdings across promoter and public categories.
Sanofi India Ltd scheduled a board meeting for August 4, 2026. The meeting will consider and approve unaudited financial results for the period ending June 30, 2026.
Sanofi India received a favourable Income Tax Appeal order dropping a demand of Rs. 72,71,510 for AY 2019‑20. The company says there is no material impact.
Sanofi India's refund claim of ₹0.12 Crore was rejected by State GST Ahmedabad. The company intends to file an appeal.
Sanofi India received a favorable order dropping a ₹0.11 Crore GST demand for FY 2018-19. The authority accepted the company's submissions, resulting in no material financial impact.
Sanofi India appointed Mr. Debajit Roy as Sales & Customer Engagement Head – Diabetes, effective June 8, 2026. He joins from Glenmark Pharmaceuticals with 20 years experience.
Tax authorities dropped a ₹0.60 Crore demand against Sanofi India regarding FY 2020-21 GST discrepancies. The resolution removes a potential liability with no material financial impact.
Sanofi India Limited appointed Mr. Rahul Bhatnagar as Chairman of the Board effective April 30, 2026. He succeeds Mr. Aditya Narayan, who completed a ten-year tenure. Additionally, Independent Director Mrs. Usha Thorat's tenure concluded on April 29, 2026. These leadership changes aim to drive strategic growth and excellence in the company's healthcare mission.
Sanofi India Limited announced the voting results of its 70th AGM, where shareholders approved all 11 resolutions with requisite majority. Key approvals included the adoption of FY2025 financial statements and the declaration of a final dividend of Rs.48 per equity share.
Sanofi India Limited concluded its 70th Annual General Meeting on April 29, 2026. Shareholders approved 11 resolutions, including the adoption of FY2025 financial statements, confirmation of an interim dividend, and declaration of a final dividend. The meeting also addressed key leadership changes, including the appointment of new directors and the upcoming transition of the Board Chairman.
Sanofi India Limited announced leadership changes effective late April 2026. Independent Directors Aditya Narayan and Usha Thorat will conclude their tenures on April 29, 2026. Consequently, Mr. Rahul Bhatnagar, currently an Independent Director, has been appointed as the new Chairman of the Board effective April 30, 2026.
Sanofi India Limited announced a leadership transition as independent directors Mr. Aditya Narayan and Mrs. Usha Thorat complete their tenures on April 29, 2026. Consequently, Mr. Rahul Bhatnagar, currently an Independent Director, has been appointed as Chairman of the Board effective April 30, 2026.
Sanofi India Ltd reported revenue from operations of ₹472.3 Cr (-11.9% YoY) and net profit of ₹102.6 Cr (-14.1% YoY) for Q4 FY26.
Sanofi India Limited reported a total income of ₹476.7 Crore for the quarter ended March 31, 2026. Net profit for the period stood at ₹102.6 Crore. The company also announced the appointment of Mr. Rahul Bhatnagar as Chairman, effective April 30, 2026, following the completion of tenures for two independent directors.